Weekly Paclitaxel plus Bevacizumab versus Docetaxel as
Second or Third-Line Treatment in Advanced Non-Squamous
Non-Small Cell Lung Cancer (NSCLC): Results from the Phase III
Study IFCT-1103 ULTIMATE